Allurion Stock Soars 70% on Weight-loss Therapy Update
Top Gap Ups and Downs on Thursday: ASML, GE, AMAT and More
This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly. -- Barrons.com
Sales are disappointing, and the market scale is questionable....... The trade of overseas weight-loss drug stocks is cooling down.
Due to disappointing clinical trial results for new drugs and sales data below expectations for two consecutive quarters, the stock prices of Novo-Nordisk A/S and Eli Lilly and Co have fallen from their historical highs. Novo-Nordisk A/S has missed out on the top spot in the European stock market, and stocks related to weight loss drugs have entered bear market territory.
Novo Nordisk Very Interested in Small Nuclear Reactors, Chairman Says -- Market Talk
Novo Nordisk Inks License Agreement For Sickle Cell Disease Candidate
